Akros SCHK HK-U.S. Biotech Index

Q2 2026 earnings release and conference call on August 6, 2026, scheduled.

Q2 2026 earnings release and conference call on August 5, 2026; low impact is estimated as the announcement is a routine scheduling event, scheduled.

Amgen is scheduled to report its Q2 2026 financial results after the market closes on August 4, 2026; a high impact is estimated as quarterly earnings typically drive significant volatility, scheduled.

Q2 2026 earnings release and conference call scheduled. Earnings announcements typically trigger price movements of 5% or more, justifying a medium importance estimate scheduled.

Q2 2026 earnings release and conference call on 2026-08-04 scheduled.

AbbVie to announce second-quarter 2026 financial results before the market opens on 2026-07-31. High importance estimated due to potential for significant volatility following the report, scheduled.

As earnings releases typically result in a 5-10% price impact, the Q2 2026 earnings release and conference call on July 30, 2026, is scheduled.

Abbott reported Q2 2026 adjusted EPS of $1.31, beating estimates of ~$1.28, and raised its full-year 2026 adjusted EPS guidance to $5.45-$5.60. This guidance raise is estimated to cause a 5-9% price impact expected.

Positive results from the Phase 3 KEYNOTE-C93 trial for Keytruda in dMMR endometrial cancer patients are expected. High impact (>10%) estimated due to significant market expansion expected.

Johnson & Johnson reported Q2 2026 revenue of $25.3 billion (+6.6% YoY) and adjusted EPS of $2.90, beating analyst estimates. The company raised its full-year 2026 guidance for both sales and earnings.

The ex-dividend date for a quarterly cash dividend of $0.63 per share is July 15, 2026. Routine dividends typically have a price impact of 1-4% scheduled.

The U.S. Food and Drug Administration (FDA) accepted the New Drug Application (NDA) for mezigdomide on July 13, 2026, for patients with relapsed or refractory multiple myeloma. The target action date is May 13, 2027.